Dimitar Penkov

Dr. Dimitar Penkov

Pharmaceutical technology and biopharmacy, Medical University of Plovdiv, Plovdiv, Bulgaria
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Radka Petkova BoyuklievaRadka Petkova Boyuklieva
Radka Petkova Boyuklieva
Nikolay ZaharievNikolay Zahariev
Nikolay Zahariev
PSPlamen Rosenov Simeonov
Plamen Rosenov Simeonov
Dimitar PenkovDimitar Penkov
Dimitar Penkov
Plamen KatsarovPlamen Katsarov
Plamen Katsarov
Nanotherapeutics have emerged as novel unparalleled drug delivery systems (DDSs) for the treatment of neurodegenerative disorders. By applying different technological approaches, nanoparticles can be engineered to possess different functionalities. In recent years, the developed, stimuli-responsive nanocarriers stand out as novel complex DDSs ensuring selective and specific drug delivery in response to different endogenous and exogenous stimuli. Due to the multifaceted pathophysiology of the nervous system, a major challenge in modern neuropharmacology is the development of effective therapies ensuring high efficacy and low toxicity. Functionalization of the nanocarriers to react to specific microenvironmental changes in the nervous system tissues or external stimulations significantly enhances the efficacy of drug delivery. This review discusses the microenvironmental characteristics of some common neurological diseases in-depth and provides a comprehensive overview on the progress of the development of exogenous and endogenous stimuli-sensitive nanocarriers for the treatment of Alzheimer’s and Parkinson’s disease.

1 December 2018 in Folia Medica
Verified
Journal Article
Open access
PDF file
Dimitar PenkovDimitar Penkov
Dimitar Penkov
Velichka AndonovaVelichka Andonova
Velichka Andonova
DDDelian Delev
Delian Delev
IKIlia Kostadinov
Ilia Kostadinov
MKMargarita Kassarova
Margarita Kassarova
Background: Betula pendula is widespread in Europe and Asia. It has been used in traditional medicine since ancient times. Birch leaf extracts are known to exhibit a number of pharmacological activities. Antioxidant activity has also been reported. Aim: The aim of this work was to investigate the antioxidant activity of a dry leaf extract from Betula pendula Roth. Materials and methods: The total flavonoid content was determined. Some of the most commonly used methods were applied to evaluate the antioxidant capacity of the extract in vitro and in vivo. The ability of the extract to scavenge DPPH free radicals was evaluated by the method described by Brand-Williams with suitable modifications. ABTS decolorization assay was also applied. The in vivo assay was performed after acute and chronic administration of the extract into white albino rats, in a dose of 100 and 500 mg/kg bw. The antioxidant potential of the plasma was determined using FRAP reagent. Results: A total flavonoid content of 42.5 mg/g was found, expressed as quercetin. The antioxidant activity against ABTS was concentration and time dependent. For example the concentration of 200 μg/ml led to 70.95% – 99.46% scavenging activity. DPPH scavenging activity was found to be about 98% at a concentration of 80 μg/ml. The extract possesses antioxidant potential, comparable with that of Trolox, in acute application. In chronic application, poorer results are observed, probably due to biotransformation and elimination processes. Conclusion: Dried birch leaf extract has a relatively high antioxidant potential and could be used as a natural source of antioxidants.

14 September 2025 in Materials
Verified
Journal Article
Open access
PDF file
Nikolay ZaharievNikolay Zahariev
Nikolay Zahariev
Radka Petkova BoyuklievaRadka Petkova Boyuklieva
Radka Petkova Boyuklieva
Dimitar PenkovDimitar Penkov
Dimitar Penkov
Paolina LukovaPaolina Lukova
Paolina Lukova
Plamen KatsarovPlamen Katsarov
Plamen Katsarov
Neurodegenerative disorders (NDs), including Alzheimer’s disease and Parkinson’s disease, pose a significant global health challenge characterized by progressive neuronal loss and limited therapeutic options. Early diagnosis remains a considerable hurdle due to the absence of reliable biomarkers and the restrictive nature of the blood–brain barrier (BBB), which complicates effective drug delivery. Magnetic nanoparticles (MNPs), particularly those based on iron oxide, have emerged as promising tools for both diagnostic and therapeutic applications in NDs, thanks to their superparamagnetism, biocompatibility, and customizable surfaces. This review examines various synthesis strategies for MNPs, encompassing physical methods (such as lithography, ball milling, and laser ablation) and chemical approaches (co-precipitation, thermal decomposition, hydrothermal synthesis, sol–gel processes, and polyacrylamide gel techniques), while highlighting how these techniques influence particle properties. This review also explores recent advancements in surface functionalization using polymers and coatings to enhance circulation time in the bloodstream and improve BBB penetration for targeted delivery. Furthermore, it emphasizes both in vitro and in vivo applications, showcasing MNPs’ effectiveness in enhancing imaging sensitivity and enabling targeted drug and gene delivery. By linking synthesis methods, functionalization techniques, and biomedical outcomes, this review illustrates the transformative potential of MNPs as next-generation theranostic agents in precision medicine for neurodegenerative diseases.

26 August 2023 in Polymers
Verified
Journal Article
Open access
PDF file
Dimitar PenkovDimitar Penkov
Dimitar Penkov
Paolina LukovaPaolina Lukova
Paolina Lukova
Hristo ManevHristo Manev
Hristo Manev
SDStela Dimitrova
Stela Dimitrova
MKMargarita Kassarova
Margarita Kassarova
The aim of the study was to develop polymer matrix tablets with modified release of dry Betula pendula leaf extract and to investigate basic parameters influencing the drug release pattern. To fully assess the statistical significance of the influence of the individual factors in the tablet formulation development as well as the combination of them, Tukey’s tests and a complete 33 factor analysis of variance (ANOVA) were applied. The following three factors were studied at three levels (low, medium and high): influence of the hydrophobic/hydrophilic polymer ratio Ethylcellulose (EC)/Hydroxypropyl methylcellulose (HPMC) (40/60, 25/75 and 10/90), influence of HPMC molecular weight (500 kDa, 750 kDa and 1150 kDa), and influence of the compression force applied (1 t, 1.5 t and 2 t). The effect of these varied parameters on the drug release parameter t80 was evaluated statistically. Twenty-seven tablet models were formulated, including all possible combinations of the variables. The obtained drug release profiles demonstrated that a 25/75 (EC/HPMC) ratio was the most suitable for prolonging the release process. Increasing the molecular weight of HMPC from 500 kDa to 750–1150 kDa and applying higher compression force significantly influenced the studied t80 values and caused sustained drug release (t80 up to 7.97 h). The combination of the hydrophilic HPMC polymer with the hydrophobic EC can result in the formation of a promising drug-carrying matrix, offering effective control of the drug release process.

17 January 2026 in Polymers
Verified
Journal Article
Open access
PDF file
Nikolay ZaharievNikolay Zahariev
Nikolay Zahariev
Dimitar PenkovDimitar Penkov
Dimitar Penkov
Radka Petkova BoyuklievaRadka Petkova Boyuklieva
Radka Petkova Boyuklieva
PSPlamen Rosenov Simeonov
Plamen Rosenov Simeonov
Paolina LukovaPaolina Lukova
Paolina Lukova
Plamen KatsarovPlamen Katsarov
Plamen Katsarov
Introduction: Magnetic nanoparticles are widely investigated as multifunctional platforms for drug delivery and theranostic applications, yet their biomedical implementation is hindered by aggregation, limited colloidal stability, and insufficient biocompatibility. Hybrid biopolymer coatings can mitigate these issues while supporting drug incorporation. Aim: This study aimed to develop casein–pullulan-coated Fe3O4 nanocomposites loaded with xanthohumol, enhancing stability and enabling controlled release for potential theranostic use. Methods: Fe3O4 nanoparticles were synthesized through co-precipitation and incorporated into a casein–pullulan matrix formed via polymer complexation and glutaraldehyde crosslinking. A 32 full factorial design evaluated the influence of casein:pullulan ratio and crosslinker concentration on physicochemical performance. Nanocomposites were characterized for size, zeta potential, morphology, composition, and stability, while drug loading, encapsulation efficiency, and release profiles were determined spectrophotometrically. Molecular docking was performed to examine casein–pullulan interactions. Results: Uncoated Fe3O4 nanoparticles aggregated extensively, displaying mean sizes of ~292 nm, zeta potential of +80.95 mV and high polydispersity (PDI above 0.2). Incorporation into the biopolymer matrix improved colloidal stability, yielding particles of ~185 nm with zeta potentials near –35 mV. TEM and SEM confirmed spherical morphology and uniform magnetic core incorporation. The optimal formulation, consisting of a 1:1 casein:pullulan ratio with 1% glutaraldehyde, achieved 5.7% drug loading, 68% encapsulation efficiency, and sustained release of xanthohumol up to 84% over 120 h, fitting Fickian diffusion (Korsmeyer–Peppas R2 = 0.9877, n = 0.43). Conclusions: Casein–pullulan hybrid coatings significantly enhance Fe3O4 nanoparticle stability and enable controlled release of xanthohumol, presenting a promising platform for future targeted drug delivery and theranostic applications.

9 October 2023 in Journal of IMAB – Annual Proceeding (Scientific Papers)
Verified
Journal Article
Closed access
DPDiana Paskaleva
Diana Paskaleva
VGVasilka Gyurova-Kancheva
Vasilka Gyurova-Kancheva
SKSlavka Kacarova
Slavka Kacarova
BPBulgaria. Unihospal Panaguirishte
Bulgaria. Unihospal Panaguirishte
BPBozhidar Pilichev
Bozhidar Pilichev
Dimitar PenkovDimitar Penkov
Dimitar Penkov
Background - hyperbaric oxygen therapy (HBOT) is a clinical method of treatment with oxygen while under increased atmospheric pressure. It has been proven as an independent therapeutic factor for a number of diseases, and in the case of COVID-19, its potential as an adjuvant therapy is still being studied. Case report – in the case of a 61-year-old man with severe pneumonia resulting from infection with COVID-19 and persisting hypoxemia and dyspnea after the acute phase. Prescribed continuous oxygenation in home conditions due to deteriorating general condition and quality of life. Undertaken additional hyperbaric oxygen therapy resulting in significant improvement after the 20th session. Conclusion - the connection between HBOT and improved paraclinical and imaging indicators, in this case, suggests conclusions of a therapeutic effect of HBOT in hypoxemia as a post-COVID symptom.